BRISTOL MYERS SQUIBB

GENESIS HEALTHCARE V. BECERRA

Our seven-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on some of Bristol Myers Squibb/Celgene’s most expensive cancer drugs? Approximately six-months after our series, which included never-before seen communications between the government and the pharmaceutical company, BMS made a major change. Now over a thousand hospitals have access to significant discounts on these drug products. Serious questions remain about allegations of drug manufacturer fraud and what took so long for BMS’s policy to change.

A two-part deep dive into one of the most important and contentious areas of the 340B program. While much of the 340B community’s attention has been focused on the contract pharmacy suits winding through the federal court system, there is other activity that the federal court system is grappling with that one could argue is equally or even more important. A federal appeals court is his hearing
arguments challenging one of the 340B program’s bedrock principles—the definition of a “patient” eligible to receive 340B drugs. 340B Report takes a close look at the groundbreaking case’s influence over the government’s position on patient definition and its far-reaching implications.

Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report